EMAT Study

Phase 2

• Conditions: Autism spectrum disorder

• Registration Number: JPRN-jRCTs052220170
• Lead Sponsor: Ikawa Daisuke

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2023-02-15
• Last Update Posted: 27 May 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

1) Autism Spectrum Disorder(ASD): Patients diagnosed by semi-structured interview and psychiatric examination using the Autism Diagnostic Observation Schedule, Second Edition (ADOS-2)
2) Patients with trauma symptoms: Not necessarily required to have experienced severe life-threatening trauma
International Trauma Interview (ITI) Part 1>=6 points and Revised Event Impact Scale Japanese version (IES-R)>=25 points.
*ITI Part 1 PTSD Assessment Section, Part 2 Complex PTSD(CPTSD) Assessment Section
3) Age: 18<=and<40
4) Gender: both
5) Patients with written consent of this clinical study

Exclusion Criteria

1) Full IQ < 70(WAIS-IV)
2) Patients with suicidal ideation and suicide attempts within the last year
3) Drug or alcohol abuse
4) Pregnant women
5) Serious physical illness
6) Personality disorder
7) A history of epileptic / convulsive seizures or their comorbidities
8) Taking drugs that lower the seizure threshold (tricyclic antidepressants, maprotiline, theophylline, methylphenidate, ketamine, clozapine, zotepine, etc.)
9) Organic brain dysfunction and lesions
10) Cardiac pacemaker
11) Internal metal objects near the stimulation site(cochlear implants, magnetic clips, deep brain stimulator, vagus nerve stimulator)
12) Patients who are disqualified as participants by the investigator or sub-investigator

Study & Design

• Study Type: Interventional
• Study Design: Not specified